Subject(s)
Anti-Bacterial Agents/pharmacology , Eye Infections, Bacterial/microbiology , Ofloxacin/administration & dosage , Pseudomonas Infections , Pseudomonas aeruginosa/drug effects , Aged , Aged, 80 and over , Drug Resistance, Microbial , Eye Infections, Bacterial/drug therapy , Female , Humans , Orbital Diseases/drug therapy , Orbital Diseases/microbiology , Pseudomonas aeruginosa/isolation & purification , Time FactorsABSTRACT
Microbiological and pharmacokinetic studies were carried out on flomoxef (FMOX, 6315-S), a new oxacephem parenteral antibiotic, in the ophthalmologic field. The results obtained are summarized as follows. FMOX has a broad antimicrobial activity spectrum against Gram-positive and Gram-negative bacteria. The MIC distribution against Staphylococcus aureus isolated from clinical cases was less than or equal to 0.20 - greater than or equal to 100 micrograms/ml with the peak value of 0.39 micrograms/ml. Concentrations of FMOX in aqueous humor and ocular tissues were determined after intravenous injection of 50 mg/kg to rabbits. FMOX showed a peak level of 2.2 micrograms/ml in the aqueous humor at 1/2 hour after administration with the ratio to serum level of 3.4%. Levels of FMOX in external and internal ocular tissues were 12.7 - 76.5 micrograms/g, less than 0.8 - 34.4 micrograms/g (ml) at 1/2 hour after administration, respectively. From these results, we concluded that FMOX may be expected to be a useful and valuable agent against infections in the ophthalmologic field.
